SCHEMBL4664239

SCHEMBL4664239

COc1ccc(NC(=O)[C@@H](C)N)cc1NS(=O)(=O)c1ccc(-c2ccc(C)o2)cc1Cl

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 3/20 0.57
LMNA P02545 4/20 0.43
MAPT P10636 3/20 0.43
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
HTT P42858 1/20 0.43
ACLY P53396 5/20 0.43
ALDH1A1 P00352 3/20 0.42
USP2 O75604 1/20 0.42
MAPK1 P28482 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
HSD17B10 Q99714 1/20 0.42
IDH1 O75874 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
AAK1 Q2M2I8 1/20 0.41
POLB P06746 2/20 0.40
TSHR P16473 1/20 0.40
GAA P10253 1/20 0.39
HPGD P15428 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14398048 1.00 GHSR (0.57) GHSRLMNAMAPTKMT2AMEN1
SCHEMBL13245980 1.00 GHSR (0.57) GHSRLMNAMAPTKMT2AMEN1
SCHEMBL13245976 0.91 GHSR (0.56) GHSRLMNAMAPTKMT2AMEN1
SCHEMBL13245992 0.91 GHSR (0.56) GHSRLMNAMAPTKMT2AMEN1
SCHEMBL14398049 0.91 GHSR (0.56) GHSRLMNAMAPTKMT2AMEN1
SCHEMBL2992486 0.90 GHSR (0.55) GHSRLMNAMAPTKMT2AMEN1
SCHEMBL2996213 0.90 GHSR (0.55) GHSRLMNAMAPTKMT2AMEN1
SCHEMBL4664086 0.88 GHSR (0.58) GHSRLMNAMAPTKMT2AMEN1
SCHEMBL2985941 0.88 GHSR (0.53) GHSRLMNAMAPTKMT2AMEN1
SCHEMBL2984160 0.88 GHSR (0.53) GHSRLMNAMAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2007716-A1 ARYL AND HETEROARYL SULPHONAMIDES AS GROWTH HORMONE SECRETAGOGUE RECEPTOR AGONISTS GLAXO GROUP LIMITED (GB) 2008-12-31 EP claimed
WO-2007118852-A1 ARYL AND HETEROARYL SULPHONAMIDES AS GROWTH HORMONE SECRETAGOGUE RECEPTOR AGONISTS GLAXO GROUP LIMITED (GB) 2007-10-25 WO claimed
US-20100179168-A1 ARYL AND HETEROARYL SULPHONAMIDES AS GROWTH HORMONE SECRETAGOGUE RECEPTOR AGONISTS BLANEY EMMA LOUISE 2010-07-15 US disclosed
US-20100179168-A1 ARYL AND HETEROARYL SULPHONAMIDES AS GROWTH HORMONE SECRETAGOGUE RECEPTOR AGONISTS BLANEY EMMA LOUISE 2010-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179168-A1 ARYL AND HETEROARYL SULPHONAMIDES AS GROWTH HORMONE SECRETAGOGUE RECEPTOR AGONISTS GHSR, GHRHR, GIPR GHSR 1/4885LMNA 4700/4885MAPT 4610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.